secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K/A
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193125-24-003344
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince provides EryDel historical financials; FY2022 loss of €12.5M
-------------------------------------------------------------------

- EryDel net loss of €12.5M in 2022 vs. €17.3M in 2021; accumulated deficit €76.5M.
- As of Dec 2022, EryDel cash €1.3M, negative equity €16.5M; operating cash flow used €11.3M.
- Quince had $83.2M cash at Sep 30, 2023, expected to fund EryDex Phase 3 trial into at least 2026.
- Acquisition adds EryDel's Red Cell Loader platform and Phase 3 therapy for Ataxia-Telangiectasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524003344/0001193125-24-003344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524003344/d109820d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer